Get the Stockscreener App
198.99
1.86%
-3.77
After Hours:
198.99
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $198.99, with a volume of 1.28M.
It is down -1.86% in the last 24 hours and up +6.82% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
See More
Previous Close:
$202.76
Open:
$201.19
24h Volume:
1.28M
Relative Volume:
0.86
Market Cap:
$28.86B
Revenue:
$5.54B
Net Income/Loss:
$1.52B
P/E Ratio:
19.18
EPS:
10.3734
Net Cash Flow:
$1.74B
1W Performance:
-2.39%
1M Performance:
+6.82%
6M Performance:
-22.75%
1Y Performance:
-22.40%
1-Day Range:
$198.22
$203.04
1-Week Range:
$190.25
$203.88
52-Week Range:
$180.26
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
198.99 | 29.41B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
345.42 | 142.49B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
158.17 | 44.07B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
70.26 | 34.44B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
39.79 | 34.76B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | JP Morgan | Overweight |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
ResMed stock trades steady as sleep apnea demand supports earnings - ad-hoc-news.de
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
Is ResMed Stock a Buy After the Noctrix Acquisition? - TIKR.com
RBC Downgrades ResMed to Sector Perform From Outperform, Cuts Price Target to $234 From $276 - Moomoo
Resmed to sell MatrixCare business to PE firm Frazier Healthcare Partners - DOTmed
ResMed stock stabilizes as investors weigh recent growth and margin trends - ad-hoc-news.de
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
ResMed downgraded at RBC Capital Markets on FY27 challenges - MSN
Precision Trading with Resmed Inc. (RMD) Risk Zones - Stock Traders Daily
ResMed stock downgraded at RBC Capital Markets (RMD:NYSE) - Seeking Alpha
FDA issues early alert for certain Resmed Astral ventilators - MassDevice
How much could ResMed shares rise according to Morgans? - The Motley Fool Australia
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
Mizuho Adjusts Price Target on ResMed to $220 From $235, Maintains Outperform Rating - Moomoo
ResMed shares rise over 3% as $490 million MatrixCare divestment fuels buybacks - Traders Union
ResMed Inc (NYSE:RMD) Offers a Quality Dividend Built on Strong Profitability and Financial Health - ChartMill
Why Is ResMed Stock Down Today? - Kalkine
Health Check: Restless investors question sleep giant Resmed’s short-term prospects - Stockhead
ResMed (ASX:RMD) Falls — What Is Behind the Medical Device Giant’s Session Decline? - Kalkine
What Puts ResMed (ASX:RMD) At The Heart Of Healthcare Reset? - Kalkine Media
ResMed Price Target Cut 1.8% to A$40.97/Share by Morgans - Moomoo
Baird Adjusts ResMed Price Target to $217 From $225, Maintains Neutral Rating - Moomoo
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Eli Lilly & Co (LLY) - The Globe and Mail
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
Cleveland Medical Devices Won Favorable PTAB Outcomes In 5 Of 6 Resmed IPR Challenges - TradingView
Cleveland Medical Devices Reports Favorable PTAB Outcomes in Five of Six ResMed IPR Challenges - PR Newswire
Citi Downgrades ResMed to Neutral From Buy; Price Target Is AU$34 - Moomoo
Citigroup Downgrades ResMed to Neutral From Buy, Adjusts Price Target to $235 From $270 - Moomoo
ResMed Price Target Cut to $235.00/Share From $270.00 by Citigroup - Moomoo
ResMed Inc. (RMD) Stock Analysis: Navigating a 25.60% Potential Upside Amidst Strong Healthcare Sector Growth - DirectorsTalk Interviews
ResMed stock reflects steady demand for sleep apnea solutions - ad-hoc-news.de
Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34 - marketscreener.com
ResMed (ASX:RMD) Falls Almost 5% as Healthcare Stocks Become One of the ASX's Biggest Drags - Kalkine
ResMed Stock Sinks as Citi Sounds Supply Alarm - TipRanks
ResMed Inc. stock falls Wednesday, underperforms market - MSN
In an era of ‘baddies,’ companies are racing to keep up with the influencer economy - CNN
How Investors Are Reacting To ResMed (RMD) Selling MatrixCare To Refocus On Core Sleep Health - Sahm
ResMed (RMD) Divestiture of MatrixCare presentation Summary - Quartr
ResMed Is Maintained at Hold by Jefferies - Moomoo
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care - Yahoo Finance
Jefferies Adjusts Price Target on ResMed to $225 From $240 - marketscreener.com
ResMed (RMD) Sells MatrixCare To Refocus On Sleep And Respiratory Health - Yahoo Finance
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Hold from Morgan Stanley - The Globe and Mail
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from Ord Minnett - The Globe and Mail
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from Macquarie - The Globe and Mail
ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
ResMed (RMD) After Russell Growth Index Exits Is The Undervalued Narrative Still Intact - simplywall.st
ResMed Analyst Backs Portfolio Reset - Benzinga
ResMed's Q4 2026 Earnings: What to Expect - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Prime Medicine, Inc. (PRME) - The Globe and Mail
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):